December 17, 2020 - An FDA advisory panel voted overwhelmingly today to recommend emergency use authorization of Moderna's mRNA 1273 COVID-19 vaccine, with 20 members in favor, and none officially opposing the opinion that the vaccine's benefits "Outweigh its risks for use in individuals 18 years of age and older."
The Moderna vaccine shares much in common with the Pfizer vaccine, including the involvement of fetal tissue in its testing.
The Spike protein is involved in the Moderna vaccine's mRNA technology, which is also used by the Pfizer vaccine.
The Moderna vaccine has caused pain at the injection site in more than 9 in 10 participants, fatigue in almost 7 in 10, and headaches or muscle pain in about 6 in 10, according to the FDA. "More than 44 percent of people who received the vaccine reported experiencing joint pain and over 43 percent reported chills," reported CNBC. However, up to almost 10 percent of participants experienced "Serious adverse reactions," which included intractable nausea and vomiting, facial swelling and rheumatoid arthritis.
It should be noted that neither vaccine trials for the Moderna vaccine nor for the Pfizer vaccine were conducted with pregnant women or immunocompromised individuals.
The major difference between the two vaccines is that the Moderna vaccine can be stored at more practical temperatures - around −4°F - while the Pfizer vaccine must be stored at −94°F, ABC News reported.
FDA approves emergency use of Pfizer vaccine tested on cell line of aborted baby.
Friday, December 18, 2020
FDA advisory panel recommends emergency use authorization of Moderna COVID-19 vaccine
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment